Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses

Baca-Estrada, Maria E.; Földvári, Marianna; Snider, Marlene; Harding, K. M.; Kournikakis, Bill; Babiuk, Lorne A.; Griebel, Philip

doi:10.1016/s0264-410x(00)00019-0

Cited by 66 publications

(32 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, owing to reports of the reactogenicity and inefficacy of whole killed-cell vaccines against pneumonic plague, the previously licensed plague vaccine USP containing iYp was discontinued in the United States. In contrast, other studies have provided evidence that iYp can protect against pneumonic plague (3,9,38,39). These latter studies were performed using parenteral administration of iYp, and only one study reported protection by administering iYp in s.c. prime-i.n.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intranasal Administration of an Inactivated Yersinia pestis Vaccine with Interleukin-12 Generates Protective Immunity against Pneumonic Plague

Kumar

Kirimanjeswara

Metzger

2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

Inhalation of Yersinia pestis causes pneumonic plague, which rapidly progresses to death. A previously licensed killed whole-cell vaccine is presently unavailable due to its reactogenicity and inconclusive evidence of efficacy. The present study now shows that vaccination intranasally (i.n.) with inactivated Y. pestis CO92 (iYp) adjuvanted with interleukin-12 (IL-12) followed by an i.n. challenge with a lethal dose of Y. pestis CO92 prevented bacterial colonization and protected 100% of mice from pneumonic plague. Survival of the vaccinated mice correlated with levels of systemic and lung antibodies, reduced pulmonary pathology and proinflammatory cytokines, and the presence of lung lymphoid cell aggregates. Protection against pneumonic plague was partially dependent upon Fc receptors and could be transferred to naïve mice with immune mouse serum. On the other hand, protection was not dependent upon complement, and following vaccination, depletion of CD4 and/or CD8 T cells before challenge did not affect survival. In summary, the results demonstrate the safety, immunogenicity, and protective efficacy of i.n. administered iYp plus IL-12 in a mouse model of pneumonic plague.

show abstract

Section: Discussionmentioning

confidence: 99%

“…challenge with Y. pestis strain 195/P, but lower doses that would be appropriate for human use failed to induce protection. Another study by Baca-Estrada et al (3) showed that mice could be partially protected against i.n. Y. pestis strain GB challenge when liposome-encapsulated killed organisms were delivered i.n.…”

mentioning

confidence: 98%

Intranasal Administration of an Inactivated Yersinia pestis Vaccine with Interleukin-12 Generates Protective Immunity against Pneumonic Plague

Kumar

Kirimanjeswara

Metzger

2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…In contrast, liposomes require the inclusion of other immunostimulants or targeting molecules (e.g., cholera toxin B, interleukin-2, monophosphoryl lipid A) to bolster their efficacy as mucosal adjuvants. 14,15,21,29,37,[54][55][56] Also, the unique characteristics of archaeal polar lipids (ether bonds, saturated phytanyl chains, membrane spanning vesicle layer) confer better stability (no oxidation, resistance to phospholipases and bile salts, stability over a wide range of pH and in serum, and better thermal stability) to the archaeosomes/AMVAD system, compared with ester lipid liposomes and cochleates. 35,36,44,45,57,58 Further, AMVAD formulations are stable at 5°C for at least one year.…”

Section: Potential Of C-di-gmp As a Mucosal Adjuvantmentioning

confidence: 99%

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Chen¹,

Patel²,

Yan³

et al. 2010

Human Vaccines

View full text Add to dashboard Cite

“…Addition of the adjuvant monophosphoryl lipid A to VTEC antigen formulated in liposomes induced significant systemic and mucosal antibody responses in mice immunized orally [155]. IN immunization of mice with a commercial inactivated Yersinia pestis vaccine in liposomes resulted in significant enhancement of IgG and IgA titers in lung and nasal washes of immunized mice [7]. Interestingly, IN immunization of mice with liposome-encapsulated plasmid DNA encoding influenza hemagglutinin conferred complete protection while all mice immunized with naked plasmid died [169].…”

Section: Liposomesmentioning

confidence: 99%

Mucosal delivery of vaccines in domestic animals

et al. 2006

Self Cite

View full text Add to dashboard Cite

-Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although highly beneficial for achieving protective immunity, the induction of mucosal immunity, especially in the gastro-intestinal tract, still remains a difficult task. As a result, only very few mucosal vaccines are commercially available for domestic animals. Here, we critically review various strategies for mucosal delivery of vaccines in domestic animals. This includes live bacterial and viral vectors, particulate delivery-systems such as polymers, alginate, polyphosphazenes, immune stimulating complex and liposomes, and receptor mediated-targeting strategies to the mucosal tissues. The most commonly used routes of immunization, strategies for delivering the antigen to the mucosal surfaces, and future prospects in the development of mucosal vaccines are discussed. mucosal / vaccine / livestock / animals / review

show abstract

Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses

Cited by 66 publications

References 16 publications

Intranasal Administration of an Inactivated Yersinia pestis Vaccine with Interleukin-12 Generates Protective Immunity against Pneumonic Plague

Intranasal Administration of an Inactivated Yersinia pestis Vaccine with Interleukin-12 Generates Protective Immunity against Pneumonic Plague

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Mucosal delivery of vaccines in domestic animals

Contact Info

Product

Resources

About